Sensorion SA

Sensorion SA pioneers gene therapies and small molecules to restore hearing and prevent hearing loss, advancing SENS‑501, SENS‑601 and SENS‑40 in clinical trials.

Sensorion SA leads biotech breakthroughs in inner‑ear care, from SENS‑401 trials for SSNHL and cisplatin ototoxicity to OTOF‑GT gene therapy, reshaping hearing health worldwide.

Sensorion’s SENS‑501 trial clears safety hurdles, boosting confidence in its vestibular‑ear therapy and driving a 217% stock swing as biotech hopes rise.

Sensorion SA, a biopharmaceutical company focused on treating inner ear diseases, faces financial challenges and uncertainty, but remains committed to innovation and development.